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Objectives The aim of this study was to evaluate the impact of the phosphodiesterase (PDE) inhibi-
tor pentoxifylline on platelet function proﬁles in patients receiving dual antiplatelet therapy (DAPT).
Background Previous studies have shown that, in patients receiving DAPT, the adjunctive use of a
PDE inhibitor enhances platelet inhibition, particularly in those presenting with diabetes mellitus
(DM). However, the pharmacodynamic (PD) effects of the PDE inhibitor pentoxifylline on platelet
function proﬁles in DM patients receiving DAPT are unknown.
Methods This was a prospective, randomized, double-blind, parallel design study conducted in DM pa-
tients with stable coronary artery disease receiving DAPT. Patients were randomly assigned to
either pentoxifylline 400 mg or placebo 3 times daily for 14 days. The PD effects were assessed
by vasodilator-stimulated phosphoprotein phosphorylation assay, light transmittance aggregometry,
VerifyNow P2Y12 assay (Accumetric, Inc., San Diego, California), and multiple electrode aggregometry at
baseline and 14 days. The PD effects were also assessed according the presence or absence of high on-
treatment platelet reactivity status.
Results A total of 40 patients were available for analysis. At 14 days, there were no differences in the
P2Y12 reactivity index as assessed by vasodilator-stimulated phosphoprotein phosphorylation between
treatment groups (primary endpoint; p  0.93). Intra-group comparisons also failed to show any differ-
ences between baseline and 14-day P2Y12 reactivity index assessment in the placebo and pentoxifylline
rms (p  0.61). There were no signiﬁcant inter- and intra-group differences in all other PD measures.
The PD effects did not vary according the presence or absence of high on-treatment platelet reactivity.
Conclusions Adjunctive treatment with pentoxifylline is not associated with increased platelet in-
hibitory effects in DM patients with coronary artery disease receiving DAPT. (J Am Coll Cardiol Intv
2011;4:905–12) © 2011 by the American College of Cardiology Foundation
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906Dual antiplatelet therapy (DAPT) with aspirin and clopi-
dogrel improves clinical outcomes in high-risk patients,
such as those with acute coronary syndrome and undergoing
percutaneous coronary intervention (1). However, despite
the clinical benefit associated with this treatment regimen,
there are still a considerable number of patients who
continue to have recurrent ischemic events (2,3). Numerous
investigations have demonstrated that the presence of high
on-treatment platelet reactivity (HPR) among patients re-
ceiving DAPT to be an independent predictor of adverse
outcomes, including stent thrombosis (3). This phenome-
non occurs more frequently among certain populations, such
as those with diabetes mellitus (DM), underscoring the
need for achieving more optimal platelet inhibitory effects
particularly in these high-risk patients (4–10).
Phosphodiesterase (PDE) in-
hibitors such as cilostazol, a PDE3
inhibitor, and pentoxifylline, a non-
selective PDE inhibitor commonly
used for treatment of intermittent
claudication, have antiplatelet prop-
erties that some studies have sug-
gested to be more pronounced in
patients with DM (11,12). Several
reports have shown that, in pa-
tients receiving DAPT, the ad-
junctive use of cilostazol (“triple
antiplatelet therapy”) enhances
platelet inhibition (7,11,13–15).
Although controversies exist on
the clinical benefit of adjunctive
cilostazol therapy (16), most stud-
ies have shown improved out-
comes in high-risk settings—
particularly in DM patients—
without any increase in bleeding
(17–22). However, cilostazol
therapy is associated with a
high incidence of nonbleeding
ide effects, such as headaches, palpitations, and tachy-
ardia, which frequently lead to treatment discontinua-
ion. Compared with cilostazol, pentoxifylline is less
xpensive and associated with fewer side effects, explain-
ng its broader use in clinical practice for the treatment of
elief of peripheral vascular disease symptoms (23). How-
ver, whether adjunctive pentoxifylline therapy in pa-
ients receiving DAPT is associated with enhanced plate-
et inhibition is unknown. The aim of the present
harmacodynamic (PD) investigation was to evaluate the
mpact on platelet function profiles associated with ad-
unctive pentoxifylline treatment in DM patients with
oronary artery disease (CAD) receiving DAPT with
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
CAD  coronary artery
disease
cAMP  cyclic adenosine
monophosphate
DAPT  dual antiplatelet
platelet therapy
DM  diabetes mellitus
HPR  high on-treatment
platelet reactivity
LTA  light transmittance
aggregometry
MEA  multiple electrode
aggregometry
PGE1  prostaglandin E1
PRP  platelet-rich plasma
PRI  P2Y12 reactivity index
VASP-P  phosphorylation of
vasodilator-stimulated
phosphoproteinspirin and clopidogrel.ethods
Patient population. This was a prospective, randomized,
ouble-blind, parallel design PD study. Patients with type 2
M were eligible for the study if they were between 18 and
0 years of age, had stable CAD, and were receiving
tandard DAPT with aspirin (81 mg/day) and clopidogrel
75 mg/day) for at least 30 days. All patients had previously
ndergone coronary stenting and were clinically stable.
atients needed to be taking hypoglycemic treatment (oral
edications or insulin) for at least 30 days. General major
xclusion criteria included: known allergies to aspirin, clopi-
ogrel, or pentoxifylline; left ventricular ejection fraction
30%; blood dyscrasia; serum creatinine level 2 mg/dl;
ctive bleeding or bleeding diathesis; gastrointestinal bleed,
emodynamic instability, or acute coronary event within 6
onths; cerebrovascular accident within 3 months; any
alignancy; concomitant use of other antithrombotic drugs
oral anticoagulants, dypiridamole, ticlopidine, or cilosta-
ol); recent treatment (30 days) with a glycoprotein
Ib/IIIa antagonist; platelet count100 103/l; and liver
disease (baseline alanine transaminase 2.5 times the upper
limit of normal). Patients were recruited from the outpatient
cardiology clinic of the University of Florida College of
Medicine–Shands Jacksonville Hospital.
Patients were randomized to receive pentoxifylline 400
mg or matching placebo capsules 3 times daily for 14 days.
Pentoxifylline 400 mg 3 times daily was chosen because this
is the Food and Drug Administration recommended dose
for the treatment of patients with intermittent claudication
on the basis of chronic arterial disease of the limbs. The
randomization and consecutive preparation of the study
medication were performed by the pharmacy of our Uni-
versity Hospital. Pentoxifylline and matching placebo were
identical-appearing white capsules. Investigators, laboratory
personnel, and patients were blinded to treatment assign-
ments. Unblinding was performed only at the end of the
study for data analysis purposes. Platelet function was
performed at 2 time points: 1) at baseline (before random-
ization); and 2) 14 days (after randomization). Patient
compliance with antiplatelet treatment was assessed by
interview and pill counting.
The study complied with the Declaration of Helsinki,
was approved by the Institutional Review Board of the
University of Florida College of Medicine–Jacksonville, and
all patients gave their informed written consent. An inde-
pendent data safety monitoring committee was instituted
for adjudication of adverse events.
Endpoints and sample size calculation. The primary end-
point of this study was the comparison of the P2Y12 reactivity
index (PRI) determined by whole blood vasodilator-stimulated
phosphoprotein between groups after 2 weeks of treatment
with pentoxifylline or placebo. Assuming that the PRI SD
is 10, we would be able to detect a difference between groups
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907of 15% with 20 patients/group with a 90% power and a
2-tailed p value 0.05. A difference in PRI of 15% was
chosen on the basis of the results obtained with cilostazol in
our previous study in DM (7). This assumes that the data
are analyzed as a parallel design. Other endpoints included
comparisons in platelet function profiles with other assays,
including light transmittance aggregometry (LTA), multi-
ple electrode aggregometry (MEA), and VerifyNow P2Y12
assay (Accumetrics, Inc., San Diego, California). Overall,
these assays enable a comprehensive assessment of platelet
function profiles, because they measure purinergic and
non-purinergic mediated signaling.
Blood sampling and functional assessments. Peripheral ve-
nous blood samples were drawn with a loose tourniquet to
avoid artifacts through a short venous catheter inserted into
a forearm vein. The first 2 to 4 ml of blood was discarded to
avoid spontaneous platelet activation. Samples were pro-
cessed within 1 h after blood-drawing.
PRI. The PRI was calculated as a measure of the functional
tatus of the P2Y12 signaling pathway. The PRI was
determined through assessment of phosphorylation status of
vasodilator-stimulated phosphoprotein (VASP-P), a key
and specific intra-platelet mediator of P2Y12 signaling,
ccording to standard protocols (6–8). In brief, VASP-P
as measured by quantitative flow cytometry (Beckman
oulter FC500, Miami, Florida) with commercially avail-
ble labeled monoclonal antibodies (Biocytex, Inc., Mar-
eille, France). The PRI was calculated after measuring the
ean fluorescence intensity (MFI) of VASP-P levels after
hallenge with prostaglandin E1 (PGE1) and PGE1 plus
denosine diphosphate (ADP). The PGE1 increases
ASP-P levels through stimulation of adenylate cyclase,Figure 1. Flow Diagram and Subject Dispositionhereas ADP binding to purinergic receptors leads to
nhibition of adenylate cyclase. Therefore, the addition of
DP to PGE1-stimulated platelets reduces levels of PGE1-
induced VASP-P. The PRI was calculated as follows: ([MFI
PGE1]  [MFI PGE1  ADP]  [MFI PGE1])  100.
Elevated PRI values indicate upregulation of the P2Y12
signaling pathway (6,7,8).
LTA. Platelet aggregation was performed with LTA ac-
ording to standard protocols (6,7,8). In brief, platelet
ggregation was assessed with platelet-rich plasma (PRP)
y the turbidimetric method in a 2-channel aggregometer
Chrono-Log 490 Model, Chrono-Log Corp., Havertown,
ennsylvania). The PRP was obtained as a supernatant after
entrifugation of citrated blood at 800 rpm for 10 min. The
solated PRP was kept at 37°C before use. Platelet-poor
lasma was obtained by a second centrifugation of the blood
raction at 2,500 rpm for 10 min. Light transmission was
djusted to 0% with PRP and to 100% for platelet-poor
lasma for each measurement and assessed after challenge
ith ADP (5 and 20 mol/l) (6–8). The results were
reported as maximal percentage platelet aggregation (6–8).
MEA. Blood was collected in hirudin treated tubes. The
EA was assessed in whole blood with the Multiplate
nalyzer (Dynabyte Medical, Munich, Germany) as previ-
usly described (24). This instrument can perform up to 5
arallel aggregometry measurements, assessing the change
n impedance caused by the adhesion of platelets onto sensor
nits formed by silver-covered electrodes. The following
gonists were used: 0.5 mmol/l arachidonic acid, 6.4 mol/l
ADP with and without 9.4 nmol/l PGE1, 32 mol/l
hrombin receptor activating peptide, and 3.2 g/ml colla-
en. Curves were recorded for 6 min, and platelet aggrega-
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908tion was determined as arbitrary aggregation units and area
under the curve.
VERIFYNOW P2Y12 ASSAY. The VerifyNow P2Y12 assay
(Accumetrics, Inc.) is a rapid whole-blood point-of-care
assay and was used according to the instructions of the
manufacturer (7,8). The VerifyNow P2Y12 assay reports
the results as P2Y12 reaction units. This assay mimics
urbidometric aggregation and uses disposable cartridges
ontaining 20 mmol/l ADP and 22 nmol/l PGE1. Aggre-
ation testing with ADP as a sole agonist activates P2Y1
and P2Y12 purinergic signaling, whereas adding PGE1
increases the specificity of the test for P2Y12 signaling. In a
separate channel of the cartridge in which iso-thrombin
receptor activating peptide is used as an agonist, a baseline
value for platelet function is obtained, enabling assessment
of platelet inhibition without having to wean the patient off
antiplatelet treatment.
Deﬁnition of HPR. The effects of pentoxifylline were also
assessed according to the presence or absence of HPR at
time of randomization (baseline sample). Patients were
defined as having HPR with various cutoff levels that have
been associated with increased risk of recurrent ischemic
events previously defined in the published data and/or
agreed upon in a consensus statement (2,3,8). These in-
cluded the following cutoff values: PRI 50%, P2Y12
reaction units230, LTA-ADP (20 mol/l)50%, LTA-
DP (5 mol/l) 46%, and MEA-ADP 462 area under
the curve (AUC) of arbitrary units (AU*min). The absolute
changes (Delta) from baseline value in platelet reactivity
according to the presence or absence of HPR were
calculated.
Statistical analysis. Continuous variables were expressed as a
ean  SD or median (interquartile range) when appro-
riate. Categorical variables were expressed as frequencies
nd percentages. Paired Student t test was used to compare
ontinuous variables. Comparisons between categorical
ariables were performed with McNemar test or binomial
xact test. Only patients who completed both treatment
eriods were included in the analysis. A p value 0.05 was
onsidered statistically significant. Statistical analysis was
erformed with the SPSS software (version 15.0, SPSS,
nc., Chicago, Illinois).
esults
From September 2009 to October 2010, a total of 720
patients were screened. Of these, 101 patients met study
inclusion criteria, and 55 patients were randomized in the
study. A total of 15 patients did not complete the study.
Overall, 40 patients with available PD data were studied to
test for the study hypothesis. Disposition of the study
population is illustrated in Figure 1. There were no differ-
ences in baseline demographic data between patients who
did and those who did not complete the study (data notshown). Baseline demographic data and clinical character-
istics of randomized patients are provided in Table 1.
Patients were similar for all baseline characteristics, except
for a higher prevalence of men in the placebo group. During
the study period, there were no changes in medical therapy.
There were no bleeding complications during the study.
Two patients randomized to the placebo arm developed
headache and nausea, which subsided after 2 days. How-
ever, these patients remained compliant to treatment and
completed the study. One patient randomized to pentoxi-
fylline developed nausea leading to treatment discontinua-
tion and incompletion of study protocol procedures.
At baseline, there were no differences in PD measures
between patients randomized to pentoxifylline and those
randomized to placebo (Table 2). At 14 days, there were
no differences in PRI between treatment groups (primary
endpoint; p  0.93) (Fig. 2). Intra-group comparisons
also failed to show any differences between baseline and
14-day PRI assessment in the placebo and pentoxifylline
arms (p  0.61). Furthermore, there were no significant
ifferences in the absolute changes in PRI at baseline and
Table 1. Baseline Demographic Data and Clinical Characteristics
Variable
Pentoxifylline
(n  22)
Placebo
(n  18) p Value
Age (yrs) 62.7 8.6 61.8 8.5 0.76
Male 7 (32) 15 (83) 0.02
Race
Caucasian 13 (59) 11 (61) 1.00
African-American 7 (32) 6 (33) 1.00
Hispanic 1 (4.5) 0 (0) 1.00
Asian 1 (4.5) 1 (6) 1.00
Risk factors/past medical history
Smoking 5 (23) 6 (33) 0.49
Hyperlipidemia 21 (96) 18 (100) 1.00
Hypertension 21 (96) 18 (100) 0.26
Body mass index 36.0 10.2 32.9 4.6 0.21
Prior myocardial infarction 14 (64) 12 (67) 1.00
Prior CABG 4 (18) 5 (28) 0.71
Prior stroke 4 (18) 1 (6) 0.36
Treatment
Beta-blockers 18 (82) 15 (83) 0.27
Calcium antagonist 10 (48) 7 (39) 0.75
Nitrates 9 (41) 9 (50) 0.75
ACE inhibitors/ARB 20 (91) 16 (89) 1.00
PPI 3 (14) 7 (39) 0.14
CYP3A4 metabolizing statin 13 (59) 14 (78) 0.31
Non-CYP3A4 metabolizing statin 5 (23) 3 (17) 0.71
Oral hypoglycemic agents 17 (77) 15 (83) 0.71
Insulin therapy 7 (32) 5 (28) 1.00
Values are mean SD or n (%).
ACE angiotensin-converting enzyme; ARB angiotensin II receptor blockers;
CABG coronary artery bypass grafting; CYP3A4 cytochrome P450 3A4 isoenzyme;PPI proton pump inhibitors.
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909after treatment between the pentoxifylline and placebo arms
(1.8  15.9 vs. 1.7  12.4; p  0.99). In addition, there
were no differences at 14 days in absolute content of
VASP-P assessed with MFI PGE1 (25.6  6.3 vs. 24.0 
.3, p 0.51) and MFI PGE1ADP (9.1 4.6 vs. 8.7 5.2,
 0.82) between pentoxifylline and placebo arms. There
were no significant inter- and intra-group differences in all
other PD measures (Table 2). The SD values of PD
measures were higher than anticipated in our statistical
Table 2. Pharmacodynamic Effects of PTX Versus Placebo
Baseline
PTX Placebo p Value
LTA
ADP 20 mol/l (%) 56.6 13.2 53.8 12.6 0.51
ADP 5 mol/l (%) 45.8 13.5 41.6 13.7 0.34
MEA
AA (AU*min) 226 248 212 145 0.84
ADP (AU*min) 526 300 493 305 0.74
ADP  PGE1 (AU*min) 312 258 300 161 0.87
TRAP (AU*min) 1,161 268 1,000 337 0.11
Collagen (AU*min) 549 237 551 286 0.98
VerifyNow P2Y12 assay
P2Y12 inhibition (%) 26.4 20.9 27.7 13.2 0.95
P2Y12 reactivity units 284 96 256 83 0.34
AA  arachidonic acid; ADP  adenosine diphosphate; AUmin  area under the curve of arbit
PGE prostaglandin E1; PTX pentoxifylline; TRAP thrombin receptor agonist peptide.
Figure 2. PRI Before and After Treatment
Solid bars  pentoxifylline. Open bars  placebo. Values are expressed as
percentage of PRI. Error bars indicate SDs of the mean.assumptions. However, the post hoc power to detect the
pre-specified difference of 15% in PRI was 84% with the SD
obtained in our study.
Rates of HPR in the study population ranged from
40% to 85%, depending on the definition used (Table 3).
The absolute changes (Delta) from baseline value in platelet
reactivity according to baseline response status assessed by different
platelet function tests are shown in Figure 3.
Discussion
Pentoxifylline is a PDE inhibitor currently recommended
for the treatment of relief of peripheral vascular disease
symptoms (23). Ex vivo and in vitro investigations have
also demonstrated the antiplatelet properties of this
compound (12,25–30). However, at difference of the
PDE inhibitor cilostazol, to date there are no studies that
have assessed the impact of pentoxifylline on platelet
function profiles in patients receiving DAPT. The need
14 Days
p Value for
Intra-Group
PTX Placebo p Value PTX Placebo
57.1 12.5 50.9 11.9 0.12 0.79 0.26
47.5 13.8 40.0 13.9 0.11 0.48 0.17
203 184 178 72 0.59 0.45 0.28
447 304 412 184 0.68 0.11 0.07
305 269 282 171 0.77 0.66 0.47
1,124 266 974 301 0.12 0.49 0.69
463 177 492 189 0.65 0.04 0.18
28.2 22.6 28.4 17.3 0.98 0.85 0.62
270 98 245 72 0.39 0.23 0.79
its; LTA  light transmittance aggregometry; MEA  multiple electrode platelet aggregometry;
Table 3. Rate of HPR Assessed by Different Platelet Function Tests in
the Study Population
HPR (%)
VASP
PRI 85
LTA
ADP 20 mol/l 80
ADP 5 mol/l 40
MEA
ADP 6.4 mol/l 50
VerifyNow P2Y12 assay
P2Y12 reactivity units 60rary unVASP vasodilator-stimulated phosphoprotein; other abbreviations as in Table 2.
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910for understanding how adjunctive PDE inhibitory ther-
apies impact platelet reactivity emerges because a consid-
erable number of patients receiving DAPT persist with
HPR, which translates into an increased risk of recurrent
ischemic events (2,3). This underscores the importance of
achieving more optimal platelet inhibition in patients at
risk of having HPR despite DAPT, such as patients with
DM (31). The results of the present investigation confirm
that patients with DM have an elevated prevalence of
HPR as demonstrated in prior PD investigations (6 – 8).
However, the results of the present investigation demon-
strate that pentoxifylline is not associated with any
significant changes in platelet reactivity, irrespective of
HPR status, as assessed by multiple PD measures evaluating
purinergic and non-purinergic mediated platelet signaling.
Overall, these findings do not support the use of pentoxifylline
as an adjunctive treatment in patients receiving DAPT to
obtain more potent platelet inhibition.
Pentoxifylline acts primarily by increasing erythrocyte
flexibility, reducing blood viscosity, and inhibiting platelet
aggregation (12,25–30). An in vitro study showed that
pentoxifylline inhibits platelet aggregation more in DM
patients in comparison with non-DM subjects in a dose-
dependent manner (12). Although these effects were con-
firmed with in vitro experiments, ex vivo experiments have
Figure 3. Delta From Baseline Value in Platelet Reactivity According to Pr
Assessed by different platelet function tests in patients treated with pento
∆adenosine diphosphate (ADP)20, and ∆ADP5 are expressed as percentage
(MEA) ADP are expressed as unit and area under the curve (AU*min), respectiv
patients without high on-treatment platelet reactivity. Error bars indicate SEMbeen controversial (12,26). Several mechanisms might ex- lplain the antiplatelet properties of pentoxifylline. These
might be related to a direct effect on the platelet or mediated
by indirect actions of the drug. Pentoxifylline has been
shown to strongly directly inhibit spontaneous and induced
platelet aggregation in vitro via inhibition of membrane-
bound phosphodiesterase, leading to raised cyclic adenosine
monophosphate (cAMP) levels, thromboxane synthesis,
and increased prostacyclin (prostaglandin I2) synthesis (32).
ther studies have shown pentoxifylline to have antiplatelet
ffects that are secondary to its rheological effects. These
nclude reducing whole blood viscosity and plasma viscosity
y decreasing plasma fibrinogen concentrations (33) and red
ell deformability (25,27,32,34).
The reasons underlying the differences between cilostazol
nd pentoxifylline observed in PD studies might be related
o multiple factors. It is known that PDE 3, 4, and 5
nhibitors induce significant increases in intra-cellular
AMP levels (35). Pentoxifylline is a nonselective PDE
nhibitor (12,36). Although in our investigation intra-
latelet cAMP levels were not assessed and would have been
f additive value to interpret our study findings, prior studies
ave shown pentoxifylline to have only a weak effect on
ntra-platelet cAMP levels (27). This is in contrast to
ilostazol, a selective and potent inhibitor of PDE 3, which
as shown to be associated with marked increase in cAMP
e or Absence of High On-Treatment Platelet Reactivity
e. The values for absolute change (∆)-P2Y12 reactivity index (PRI),
values for ∆P2Y12 reaction units (PRU) and ∆multiple electrode aggregometry
olid bars  patients with high on-treatment platelet reactivity. Open bars esenc
xifyllin
. The
ely. Sevels (37). Because cAMP is a pivotal modulator of
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911VASP-P, a key mediator of P2Y12 receptor signaling, this
ight explain why studies have shown that adjunctive
reatment with cilostazol are associated with even greater
2Y12 mediated effects, compared with double-dose clopi-
ogrel regimens (13,14). These pharmacological properties
ould also explain why pentoxifylline does not have enough
vidence to improve objective (walking distance) and sub-
ective (quality of life) outcomes in patients with intermit-
ent claudication, whereas cilostazol has demonstrated ben-
fit in both, albeit at the expense of more nonbleeding side
ffects (23,38). Indeed, it might be argued that novel and
ore potent P2Y12 inhibiting strategies (e.g., prasugrel,
ticagrelor) might overcome the limitations of clopidogrel,
thus limiting the need to resorting to a third agent such as
PDE inhibitors to obtain more potent platelet inhibition
(39). However, these novel therapies are associated with an
increased risk of spontaneous bleeding (40,41), which has
not been observed with triple antiplatelet therapy (17–22),
making the latter an attractive treatment option in patients
who have an increased ischemic risk but where more potent
P2Y12 inhibitors might be contraindicated (31).
Another reason for the lack of additional platelet inhibi-
tion might be explained by the pharmacokinetic profile of
pentoxifylline. Pentoxifylline, in fact, is metabolized in
humans to at least 7 metabolites (27). The major metabo-
lites are hydroxy metabolite 3,7-dimetyl-1-(5=hydroxyhexyl)
xanthine), the 2 carboxylic acid metabolites 3,7-dimetyl-1-
(4-carboxybutyl) xanthine, 3,7-dimetyl-1-(3-carboxypropyl)
xanthine, and pentoxifylline (27,29). The main in vivo effect
on platelet aggregation is due to pentoxifylline and hydroxy
metabolite 3,7-dimetyl-1-(5=hydroxyhexyl) xanthine),
hereas the remaining metabolites contribute by 10%
ach. Pharmacokinetic studies have shown that the peak
lasma concentration of pentoxifylline is approximately 0.3
g/l at approximately 3 h after administration of 400 mg
entoxifylline (27,42). However, a previous in vitro PD
tudy showed that 0.25 mg/l and 0.5 mg/l of pentoxifylline
ere not sufficient to inhibit platelet aggregation, for which
igher levels (0.75 mg/l and 1.0 mg/l) were needed (12).
herefore, it might be hypothesized that oral administra-
ion of 400 mg pentoxifylline could not be sufficient to reach
lasma concentrations of its metabolites that can enhance
latelet inhibitory effects.
Despite the neutral findings of our study, the lack of
mpact on the PD measures in CAD patients receiving
APT also provides some reassurance. In fact, the addition
f an agent with antiplatelet properties such as pentoxifyl-
ine, albeit with the objective of relief of peripheral vascular
isease symptoms, can still raise concerns about the bleeding
otential in these patients, which is per se increased given
he use of clopidogrel on a background of aspirin therapy
43). The ever-raising concerns on the detrimental impact
f bleeding on outcomes underscore identification of pa-
ients and strategies associated with increased risk (44).ndeed, patients with DM, as studied in our current
nvestigation, have an increased risk of bleeding (45). In
ddition, they also frequently have concomitant CAD and
eripheral vascular disease, thus commonly treated with
APT as well as a PDE inhibitor, making the results of our
D investigation of potential clinical value. Indeed, our PD
tudy was not powered to make any conclusions on the
afety of pentoxifylline. However, the lack of enhanced
latelet inhibitory effects might hamper the concerns over
leeding when pentoxifylline is used at recommended doses
or its approved indication for relief of peripheral vascular
isease symptoms in patients also treated with DAPT.
Reprint requests and correspondence: Dr. Dominick J. Angio-
lillo, University of Florida College of Medicine-Jacksonville, 655
West 8th Street, Jacksonville, Florida 32209. E-mail: dominick.
angiolillo@jax.ufl.edu.
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